Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI)

W. Ammari, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Bradford, Leeds, Keighley, Huddersfield, United Kingdom)

Source: Annual Congress 2009 - New aspects of inhalation therapy
Session: New aspects of inhalation therapy
Session type: Thematic Poster Session
Number: 2046
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Ammari, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Bradford, Leeds, Keighley, Huddersfield, United Kingdom). Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI). Eur Respir J 2009; 34: Suppl. 53, 2046

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A 6 week study of the efficacy and safety of UK-500,001 dry powder for inhalation (DPI) in adults with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007


Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013


Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India
Source: Annual Congress 2006 - The challenges of managing asthma in primary care
Year: 2006


The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008


Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Exercise capacity and dyspnea challenge of adult chronic obstructive lung disease (COPD) patients when using a novel mesh nebulizer compared to traditional jet nebulizer (TJN)
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Pulmonary function response in smokers and patients with chronic obstructive lung disease (COPD) following exposure to concentrated fine (PM2.5) particles
Source: Annual Congress 2009 - Indoor and outdoor air pollution
Year: 2009


Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006


A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

The maximum % fall in FEV1 after a mannitol challenge in subjects with asthma, suspected asthma, COPD and bronchiectasis
Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control
Year: 2010


What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002



A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients
Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up
Year: 2010


Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection?
Source: Eur Respir J 2001; 18: Suppl. 33, 172s
Year: 2001

Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017

Preference and quality of life of adult chronic obstructive lung disease (COPD) patients when using a novel mesh nebulizer compared to traditional jet nebulizer (TJN)
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016